Harald Schwarz

Harald Schwarz is a graduate economist (Diplom-Volkswirt) who has spent more than 20 years working with international pharmaceutical groups and more than 20 years in the portfolio management of healthcare assets. He is a shareholder of Medical Strategy GmbH, one of Europe's longest-established independent biotech investment advisors, and was for many years one of its managing directors before stepping out of that statutory role (public register records show he ceased to be listed as a Geschäftsführer around 1 March 2023).

Medical Strategy GmbH was founded in 1992 and has managed healthcare investment funds since 2000, holding a BaFin license for financial portfolio management since 1998. The firm has grown to roughly €1.3 billion in assets under management with a small, specialized team, positioning itself as a pure-play healthcare and biotechnology equity manager. Schwarz has been part of that build-out since the fund business launched in 2000.

His public profile is that of a healthcare-fund professional rather than a startup angel. He has represented the firm publicly, including an interview at the analytica Finance Day 2016, discussing his work as a healthcare investment advisor. The firm's flagship vehicle, the MEDICAL BioHealth fund (ISIN LU0119891520), was launched on 30 October 2000 and has built a 20-plus-year track record of outperformance versus healthcare indices.

• Invests in listed small- and mid-cap biotechnology, emerging pharma and medical-technology companies — deliberately avoiding very early-stage ventures in favor of businesses "close to market launch or new to the market."
• Seeks to "identify innovations in the healthcare sector at an early stage" and generate long-term, above-average returns by buying undervalued growth companies with solid financials at the start of their growth cycle.
• Long-term, strategic orientation: the firm states that "only investors who think long-term and therefore strategically have the chance to participate in these high potentials."
• Concentrated-but-diversified public portfolios: roughly 70–150 individual securities, weighted 0.25%–5% by risk, liquidity and company size, using proprietary valuation models (innovation multiples of ~3x–6x sales).
• Therapeutic focus on high-growth segments: oncology, rare diseases, cardiometabolic, autoimmune and central-nervous-system disorders.